Elsevier

Pathology

Volume 39, Issue 1, February 2007, Pages 134-138
Pathology

Undifferentiated carcinoma of the endometrium: a review

https://doi.org/10.1080/00313020601159494Get rights and content

Summary

Undifferentiated carcinoma of the endometrium is a high grade carcinoma and under-recognised, frequently diagnosed as grade 3 endometrioid carcinoma. We have found that undifferentiated carcinoma represents 9% of all endometrial carcinomas; it is composed of solid sheets of epithelial cells and in most cases only 5-10% of the cells are positive for keratin. The recognition of undifferentiated carcinoma is extremely important when this neoplasm is associated with a grade 1 or grade 2 endometrioid adenocarcinoma. In this situation it is important to diagnose the solid areas of carcinoma as undifferentiated and avoid evaluating them as the solid component of endometrioid carcinoma because there is significant difference between the excellent prognosis of grade 2 endometrioid carcinoma, the intermediate prognosis of grade 3 carcinoma, and the poor prognosis of undifferentiated carcinoma, which in cases of association with differentiated areas should be diagnosed as dedifferentiated endometrioid carcinoma.

References (20)

There are more references available in the full text version of this article.

Cited by (112)

  • Uncommon and Difficult High-Grade Endometrial Carcinomas

    2022, Surgical Pathology Clinics
    Citation Excerpt :

    It was next recognized that undifferentiated carcinoma can be associated with low-grade endometrioid carcinoma, in which case the term “dedifferentiated carcinoma” applies.2 Before the 2020 WHO classification of female genital tract tumors, dedifferentiated carcinoma was strictly defined as composed of undifferentiated carcinoma and a low-grade endometrioid carcinoma (FIGO grade 1 or 2) components.1–4 It is now recognized that dedifferentiated carcinoma can also arise in the background of high-grade endometrial carcinoma.

  • Undifferentiated and dedifferentiated neoplasms of the female genital tract

    2021, Seminars in Diagnostic Pathology
    Citation Excerpt :

    In contrast, extrauterine disease is noted in 30% of FIGO grade 3 endometrioid adenocarcinomas while disease-related death occurs in 39% of patients.2 Conventional chemotherapy regimens have shown minimal value in the treatment of UC.4 One patient responded to radiation therapy and was disease-free at 104 months,4 but studies evaluating the efficacy of radiation are overall limited.

  • Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification

    2021, Gynecologic Oncology
    Citation Excerpt :

    From a molecular point of view, a lineage-specific mutational clustering has not been described, as well no overt cell lineage differentiation has been attributed. The loss of differentiation in UDC/DDEC is often demonstrated immunohistochemically by the loss of expression of epithelial and gynaecological markers [1–4]. Molecularly, the loss of differentiation has been associated to different genetic pathways.

  • SWI/SNF-deficient malignancies of the female genital tract

    2021, Seminars in Diagnostic Pathology
    Citation Excerpt :

    UEC may express CD34 (otherwise rarely positive in carcinomas) and cyclin D1 limiting the usefulness of these markers in the differential diagnosis with proximal type epithelioid sarcoma and YWHAE-NUTM2 rearranged high-grade endometrial stromal sarcoma, respectively.42,43 As noted previously, a characteristic feature of UEC (and the undifferentiated component of DEC) is loss of expression of the more specific differentiation markers PAX8, ER and PR.17,20,21 As with SWI/SNF complex proteins and epithelial marker expression, loss of staining is usually restricted to the undifferentiated component of DEC with retained expression in the differentiated element.

View all citing articles on Scopus
View full text